During the last session, BioAtla Inc (NASDAQ:BCAB)’s traded shares were 1.97 million, with the beta value of the company hitting 0.95. At the end of the trading day, the stock’s price was $1.39, reflecting an intraday loss of -6.08% or -$0.09. The 52-week high for the BCAB share is $4.02, that puts it down -189.21 from that peak though still a striking 17.99% gain since the share price plummeted to a 52-week low of $1.14. The company’s market capitalization is $67.20M, and the average intraday trading volume over the past 10 days was 1.51 million shares, and the average trade volume was 1.16 million shares over the past three months.
BioAtla Inc (BCAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. BCAB has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.38.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BioAtla Inc (NASDAQ:BCAB) trade information
BioAtla Inc (BCAB) registered a -6.08% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.08% in intraday trading to $1.39, hitting a weekly high. The stock’s 5-day price performance is -18.71%, and it has moved by -26.84% in 30 days. Based on these gigs, the overall price performance for the year is -13.13%. The short interest in BioAtla Inc (NASDAQ:BCAB) is 4.87 million shares and it means that shorts have 2.76 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 72.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, BCAB is trading at a discount of -259.71% off the target high and -259.71% off the low.
BioAtla Inc (BCAB) estimates and forecasts
Statistics show that BioAtla Inc has outperformed its competitors in share price, compared to the industry in which it operates. BioAtla Inc (BCAB) shares have gone down -33.81% during the last six months, with a year-to-date growth rate more than the industry average at 42.25% against 18.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 32.14% this quarter and then jump 18.75% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -25.30%. While earnings are projected to return 40.93% in 2024.
BCAB Dividends
BioAtla Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
BioAtla Inc (NASDAQ:BCAB)’s Major holders
BioAtla Inc insiders own 10.75% of total outstanding shares while institutional holders control 42.65%, with the float percentage being 47.79%. SOLEUS CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 81.0 institutions own stock in it. As of 2024-06-30, the company held over 3.9 million shares (or 8.113% of all shares), a total value of $5.34 million in shares.
The next largest institutional holding, with 1.89 million shares, is of VANGUARD GROUP INC’s that is approximately 3.9205% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.58 million.
